Many Pleural Mesothelioma Patients May Be Missing Out on Life-Extending Treatments

Too many patients with malignant pleural mesothelioma are not getting the trimodality treatment protocol that could significantly change their outcomes.

That is the finding of a newly-published study conducted at MD Anderson Cancer Center in Houston, Texas.

Researchers reviewed the records of more than 20,000 patients in the National Cancer Database with a definitive diagnosis of pleural mesothelioma between 2004 and 2014.

They discovered that, even though a combination of therapies has been shown to yield the best mesothelioma outcomes, too many patients were not being given the option of multi-modal treatment.

Mesothelioma Treatment Patterns “Vary Widely”

Among the 20,561 mesothelioma patients included in the study, only 4,028 underwent cancer-directed surgery. Of those, just 533 (2.6% of the total) received additional treatment with chemotherapy and radiotherapy. This combination in known as trimodality treatment.

“Many malignant pleural mesothelioma patients are not treated with trimodality therapy, with significant variation in treatment patterns,” writes study author David B. Nelson, MD, in the European Journal of Cardiothoracic Surgery.

Most of the mesothelioma patients who did not receive at least chemotherapy after their cancer surgery were those in the earliest cohorts. The team reports that the use of surgery with chemotherapy increased by 87 percent during the ten year study period.

Mesothelioma Survival May be Impacted

The lack of trimodal therapy for so many patients is significant because malignant mesothelioma is a rare and aggressive malignancy that rarely responds to a single type of cancer treatment.

Findings released earlier this year by the MD Anderson team demonstrated longer mesothelioma survival in patients who received a combination of cancer-directed surgery, chemotherapy, and radiation.

The impact was especially significant in those with the most common subtype of pleural mesothelioma called epithelioid mesothelioma. For these patients, trimodal therapy extended mesothelioma survival by nearly nine months from 14.5 to 23.4 months.

Older Patients Less Likely to Receive Trimodal Mesothelioma Treatment

The mesothelioma patients who were most likely to receive all three types of therapy for malignant mesothelioma were those who

Were younger than 70

Had a comorbidity (other health problems) score of 0

Had private insurance

Patients who were fortunate enough to be treated at a major academic center (where experts have more experience with mesothelioma) or those who traveled at least 26 miles for treatment were also more likely to undergo trimodal mesothelioma therapy, increasing their odds of survival.

The researchers conclude that more mesothelioma patients should be referred to “high volume and specialized centers” where they can not only access more therapeutic options like trimodal mesothelioma treatment, but where they are also more likely to have the opportunity to enroll in a clinical trial.

Source:

Nelson, DM, “Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma”, December 2, 2017, European Journal of Cardiothoracic Surgery, Epub ahead of print

"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."

— Tom Crittenden, Maricopa, Az.

*Note: We have limited copies available for free. Free copies of the book are only available in the United States, Australia and New Zealand.

Recent Article

Mindfulness May Help Mesothelioma Patients Cope

December 13, 2017

There is new evidence that lung cancer patients who receive training in mindfulness can dramatically lower their feelings of stress and anxiety. Lung-related cancers like pleural mesothelioma and non-small cell lung cancer have been shown to produce some of the highest levels of anxiety of any cancer. Although there are differences between the asbestos cancer malignant mesothelioma and other types of lung cancer, both malignancies tend … Continue reading Mindfulness May Help Mesothelioma Patients Cope»

Disclaimer

Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly, Inc. All of the information provided on this website or by an employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.